A
Aplagon
Biotech & Life Sciences · Helsinki, Finland · Founded 2009
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutic solutions for severe cardiovascular diseases MoreLess
Developer of antithrombotic compounds designed to treat complications of vascular intervention-related blood vessel occlusions. The company's compounds are engaged in developing biological mimetics of heparin proteoglycan, for the clinical management of vascular injury-related thrombotic occlusions and ischemic reperfusion injuries, enabling patients to get effective antithrombotic medicines with important safety advantages. Keywords: Pharmaceuticals and Biotechnology, Antithrombotic Compound, Biotechnology Company, Clinical Management System, Drug Discovery, Drug Discovery Firm, Vascular Disease.
Talent graph
Aplagon's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Aplagon's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Aplagon has talent and traffic
team presence
Market sentiment
What the market is saying about Aplagon
An AI-synthesized read of the highest-engagement posts about Aplagon on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aplagon on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.